Human papillomavirus infection

Oral sex is now the leading risk factor for throat cancer

Retrieved on: 
Tuesday, April 25, 2023
Infection, Oropharyngeal cancer, DNA, Tonsillectomy, Travel, Vaccination, Coronavirus, Policy, Cancer, Partner (business rank), Human papillomavirus infection, School, Cervical cancer, Patient, Time, Immune system, HPV, Ageing, Otorhinolaryngology, Mouth, Safety, Birth control, Vaccine

This has been due to a large rise in a specific type of throat cancer called oropharyngeal cancer (the area of the tonsils and back of the throat).

Key Points: 
  • This has been due to a large rise in a specific type of throat cancer called oropharyngeal cancer (the area of the tonsils and back of the throat).
  • Oropharyngeal cancer has now become more common than cervical cancer in the US and the UK.
  • For oropharyngeal cancer, the main risk factor is the number of lifetime sexual partners, especially oral sex.
  • Those with six or more lifetime oral-sex partners are 8.5 times more likely to develop oropharyngeal cancer than those who do not practise oral sex.

HPV Cancers Alliance to Congress: Eradicate HPV

Retrieved on: 
Wednesday, April 19, 2023
Anal cancer, Vaccination, FY, Education, Marcia Cross, Capitol Hill, National Breast Cancer Coalition, Cross, CDC, Congress, Cancer, Korea Disease Control and Prevention Agency, Quality of life, HPV, Cancer Moonshot, Knowledge, Health, Human papillomavirus infection, Legislation, Vaccine

WASHINGTON, April 19, 2023 /PRNewswire/ -- Emmy-nominated actress, Marcia Cross, and her partners at the HPV Cancers Alliance took to Capitol Hill today to advocate for federal funding and legislation in support of HPV awareness and the six cancers HPV causes.

Key Points: 
  • WASHINGTON, April 19, 2023 /PRNewswire/ -- Emmy-nominated actress, Marcia Cross, and her partners at the HPV Cancers Alliance took to Capitol Hill today to advocate for federal funding and legislation in support of HPV awareness and the six cancers HPV causes.
  • Emmy-nominated actress, Marcia Cross, and her partners at the HPV Cancers Alliance took to Capitol Hill today to advocate for federal funding and legislation in support of HPV awareness and the six cancers HPV causes.
  • Representative Kathy Castor (D-FL) will soon reintroduce the Promoting Resources to Expand Vaccination, Education, and New Treatments for HPV Cancers Act, or the PREVENT HPV Cancers Act .
  • The HPV Cancers Alliance supports the PREVENT HPV Cancers Act.

Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, CIN, AACR, CD1D, University, HPV16, RNA, Messenger, E7, Cervical cancer, Patient, Antigen presentation, Nutcracker, HPV, Neoplasm, Cervical intraepithelial neoplasia, Therapy, Tumor microenvironment, Human papillomavirus infection, Prostate cancer, Pharmaceutical industry, Vaccine, DRS

Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).

Key Points: 
  • Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).
  • The lead indication for NTX-250 is cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection, which can progress to cervical cancer if left untreated.
  • More than 90 percent of cervical cancer and CIN cases are linked to HPV infection, with HPV16 as the most prevalent high-risk strain.
  • Lawrence Fong and David Oh at the University of California, San Francisco — which mapped shared tumor antigen reactivity using nanoparticle-encapsulated mRNA in prostate cancer patients.

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

Retrieved on: 
Monday, April 17, 2023
Infection, Interferon gamma, Clinical trial, Cancer, Woman, CMO, OXFORD, Șaeș, Human papillomavirus infection, APOLLO, E2, CD8, ELISpot, E6, Immune system, Non-carious cervical lesions, HPV, Poster, CD4, Conference, Safety, Vaccine, Vaccitech

The APOLLO trial (also known as HPV001) is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus (HPV) infection.

Key Points: 
  • The APOLLO trial (also known as HPV001) is a fully enrolled Phase 1b/2 study of VTP-200 in women with low-grade cervical lesions associated with persistent human papillomavirus (HPV) infection.
  • “The safety and immunogenicity data presented at IPVC shows the potential of VTP-200 in treating persistent high-risk HPV (hrHPV) infections.
  • Currently, women with persistent HPV infections have no treatment options until they develop high grade lesions,” said Meg Marshall, CMO of Vaccitech.
  • In addition, intracellular cytokine staining data from the active groups showed both CD4 and CD8 responses.

Zocdoc Report: What's Up Down There?

Retrieved on: 
Monday, April 10, 2023
Well, Human papillomavirus infection, Gen, STI, Woman, Generation Z, CDC, COVID-19, Patient, HPV, Down There, Birth control

NEW YORK, April 10, 2023 /PRNewswire/ -- Post-Covid-19 lockdowns, health officials saw a spike in reported sexually transmitted infections (STIs) in 2022. Why? Well, experts say STI screenings were on the long list of healthcare appointments that patients put off during the pandemic.

Key Points: 
  • Well, experts say STI screenings were on the long list of healthcare appointments that patients put off during the pandemic.
  • Ahead of CDC's STI Awareness Week , which runs from April 9th to April 15th, " Zocdoc Reports – What's Up Down There? "
  • explores Zocdoc appointment booking data to see if patients have taken a renewed interest in their sexual health.
  • Patients on Zocdoc made the most appointments related to genital warts , which are caused by the Human Papilloma Virus (HPV).

PathoVax's Licensed HPV Vaccine Receives FDA Clearance of HPV16 RG1-VLP Investigational New Drug Application

Retrieved on: 
Wednesday, March 29, 2023
Vaccine, GMP, National Cancer Institute, HPV16, Medical school, Johns Hopkins University, Patient, Risk, Medical University of Vienna, HPV, Johns, Johns Hopkins, FDA, NCI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Human papillomavirus infection, Food, Safety, Pharmaceutical industry

BALTIMORE, March 29, 2023 /PRNewswire/ -- PathoVax LLC ("PathoVax"), a biotech company focused on developing a universally preventative Human Papillomavirus (HPV) vaccine - "RGVax", today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for its licensed monovalent component- HPV16 RG1-VLP and concluded that a Phase 1 clinical trial in the United States and Austria is now given the go-ahead to proceed.

Key Points: 
  • This Phase 1, first-in-human, global multicenter clinical study seeks to demonstrate the safety and immunogenicity responses to HPV16 RG1-VLP in healthy volunteers.
  • We are excited that our collaborators have been able to move forward with the clinical development of HPV16 RG1-VLP.
  • PathoVax was co-founded to licensed and developed a game changing preventative universal HPV vaccine.
  • Dr Joshua Wang, a co-founder of PathoVax LLC said the following "Securing FDA clearance to start clinical trials is a significant achievement.

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

Retrieved on: 
Monday, March 20, 2023
ELISPOT, Cancer, Woman, OXFORD, Șaeș, Human papillomavirus infection, E2, E6, Immune system, HPV, Conference, Vaccine, Vaccitech

“These interim data are a promising step in the right direction, and we look forward to seeing the final data in early 2024.

Key Points: 
  • “These interim data are a promising step in the right direction, and we look forward to seeing the final data in early 2024.
  • Currently people with persistent HPV infections have no treatment options until they develop high grade lesions.
  • VTP-200 was generally well-tolerated with no product-related grade 3 unsolicited events and no product-related SAEs.
  • These interim data will be presented orally at the upcoming International Papillomavirus Conference in Washington D.C., which is taking place 17-21 April 2023.

Huichao Liang, An Expert on AIDS Combined with Gynecological Oncology, Receives Excellent Popular Science Worker Award

Retrieved on: 
Friday, February 24, 2023
Guangzhou Medical University, Bacteria, STD, HIV/AIDS denialism, Control, Female, HIV, People's Hospital, Pragathi Nagar, Human papillomavirus infection, World Health Organization, Diagnosis, Pregnancy, Gynaecology, Ovarian cancer, Research, California Community College Athletic Association, Hospital, Obstetrics, International Society, HIV/AIDS, CDC classification system for HIV infection, Survival rate, Syphilis, Conditional sentence, L-theory, Patient, Hepatitis B, Endometrial cancer, WHO, AIDS, Hysterectomy, Committee, Fungal infection, Meta-analysis, HPV, Science, Infection, Multimedia, Traditional Chinese characters, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Cervical cancer, Tuberculosis, Health, Birth control, Vaccine, Pharmaceutical industry

Among gynecological tumors, cervical cancer, endometrial cancer and ovarian cancer are still the most important female reproductive system malignancies threatening women's health.

Key Points: 
  • Among gynecological tumors, cervical cancer, endometrial cancer and ovarian cancer are still the most important female reproductive system malignancies threatening women's health.
  • How to improve the survival rate and cure rate of gynecological tumor patients is the focus of research of gynecological oncology experts at home and abroad.
  • Huichao Liang spent a lot of time and energy on the integration and improvement of the medical team.
  • As an infectious disease combined with gynecological oncology expert, Huichao Liang must face the terrible viruses and bacteria and defeat them with wisdom.

BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings

Retrieved on: 
Thursday, February 9, 2023
Biomarker, Woman, STI, Laboratory, Korea Disease Control and Prevention Agency, Women's health, HPV, Patient, Health, Risk, CDC, Associate, FACOG, Reflex, FACP, FDA, Roche, Cervical cancer, MS, Human papillomavirus infection, Cancer, Ageing, Nursing, Birth control, MD

ELMWOOD PARK, N.J., Feb. 9, 2023 /PRNewswire/ -- BioReference® Health LLC, one of the largest full-service specialty laboratories in the United States, announced today it will be one of the first commercial laboratories to use offer the CINtec® PLUS Cytology test from Roche Diagnostics. CINtec PLUS Cytology is the only FDA-approved dual-stain triage test for patients who have a high-risk human papillomavirus (HPV) result. The test is commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Women's Health.

Key Points: 
  • CINtec PLUS Cytology is the only FDA-approved dual-stain triage test for patients who have a high-risk human papillomavirus (HPV) result.
  • The test is commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Women's Health.
  • Based on a patient's individual risk level, healthcare providers use screening and triage tests to identify disease risk and establish appropriate healthcare management.
  • "We know that cervical cancer is one of the most preventable forms of cancer," said Tamera Paczos, MD, MS, FACP, FACOG, Vice President, Associate Chief Medical Officer, BioReference.

$82 Billion Global Vaccines Market 2023 to 2029: Growth Trends, and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, SEARO, Influenza, Vaccine, WPRO, AMRO, Sanofi, Inactivated vaccine, Merck, Projection, COVID-19, Human papillomavirus infection, Pneumococcal conjugate vaccine, Anthrax Vaccine Immunization Program, GSK, Overalls, Mortality, PCV, Streptococcus pneumoniae, HPV, WHO, Chickenpox, Conjugate vaccine, Pharmaceutical industry

This is likely to be a continuous booster to the PCV segment in vaccines market.

Key Points: 
  • This is likely to be a continuous booster to the PCV segment in vaccines market.
  • This according to the report will act as a significant driving force for spike in demand for PCV in global vaccines market.
  • These markets are expected to capture around 50% of the overall vaccines market valuation over the next few years.
  • The report marks AMRO as the most prominent vaccines market as the region is characterized by the relatively high value for Influenza (adult), Varicella, meningococcal vaccines, and HPV.